Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01960348 · ClinicalTrials.gov registry record · Phase 3
APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis
A Phase 3 study, sponsored by Alnylam Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 225
- Enrollment target
NCT01960348 is a Phase 3 study that has completed, run by Alnylam Pharmaceuticals. The registered enrollment target is 225 participants.
The verdict
NCT01960348, a Phase 3 study, has completed, sponsored by Alnylam Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 225 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and efficacy of patisiran (ALN-TTR02) in patients with transthyretin (TTR) mediated amyloidosis. An open-label, single-arm, long-term follow-up extension study NCT02510261 (ALN-TTR02-006) was initiated to provide participants who completed this study with continued patisiran-LNP (lipid nanoparticle) treatment.
Interventions
- DRUG Sterile Normal Saline (0.9% NaCl)
- DRUG patisiran (ALN-TTR02)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 225 participants |
| Start Date | 2013-11 |
| Est. Completion | 2017-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01960348
The ClinicalTrials.gov registry entry for NCT01960348 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 225 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alnylam Pharmaceuticals, which has 49 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sterile Normal Saline (0.9% NaCl) is the first listed.
NCT01960348 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01960348 about?
NCT01960348 is a clinical study titled "APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis". The purpose of this study is to evaluate the safety and efficacy of patisiran (ALN-TTR02) in patients with transthyretin (TTR) mediated amyloidosis. An open-label, single-arm, long-term follow-up extension study NCT02510261 (ALN-TTR02-006) was initiated to provide participants who completed this stu...
What is the current status of trial NCT01960348?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 225 participants. The study started on 2013-11. Estimated completion is 2017-08.
What interventions are being tested in trial NCT01960348?
The interventions under investigation include: Sterile Normal Saline (0.9% NaCl) (DRUG), patisiran (ALN-TTR02) (DRUG).
Who is sponsoring clinical trial NCT01960348?
This trial is sponsored by Alnylam Pharmaceuticals, which has 49 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.